Albert et al. investigated TSPO PET in four patients with recurrent isocitrate dehydrogenase wildtype high-grade gliomas and found the median maximal tumor-to-background ratio to be 5.86 [43]. This evidence concerns the gene TSPO and central nervous system cancer.